To date, four cohorts of subjects have received OMS721 or placebo by subcutaneous injection at increasing dose levels. OMS721 or placebo injections were well tolerated in all subjects. No clinically significant abnormalities on laboratory tests or electrocardiograms have been observed. At the highest subcutaneous dose administered to date, OMS721 achieved serum concentrations that resulted in a high degree of inhibition of lectin pathway activation. The serum concentrations seen in the Phase 1 subjects are similar to those associated with efficacy in animal models of diseases linked to the lectin pathway, including those of TMA and neovascular age-related macular degeneration (AMD), a leading cause of vision loss in individuals over 60 years of age.
7:20AM Omeros misses by $0.02, beats on revs (OMER) 9.14 : Reports Q3 (Sep) loss of $0.46 per share, $0.02 worse than the Capital IQ Consensus Estimate of ($0.44); revenues fell 85.7% year/year to $0.2 mln vs the $0.14 mln consensus.
"For OMS302, the marketing applications were accepted for review by both the FDA and EMA, and the market launch is planned for the second half of 2014. Our OMS824 program for the treatment of cognitive disorders was granted orphan drug designation by the FDA, generated positive Phase 1 clinical trial results, began enrollment in a Phase 2 trial in patients with schizophrenia and is now initiating a Phase 2 trial in Huntington's disease. OMS721, our MASP-2 inhibitor, entered a Phase 1 clinical trial from which we reported positive data today, and a Phase 2 trial to evaluate the molecule's efficacy and safety in patients with thrombotic microangiopathies is planned for early 2014. Preclinically, our GPCR platform continued to identify functionally active compounds against an unprecedented number of orphan receptors, and our addiction and high-risk bleeding programs advanced toward the clinic. Following the close of the quarter, we added over $17 million to our balance sheet, positioning Omeros to execute on a series of value-driving milestones during the remainder of 2013 and well into 2014."
Recent OMER News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/07/2024 08:08:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/07/2024 08:06:56 PM
- Omeros Corporation Reports Second Quarter 2024 Financial Results • Business Wire • 08/07/2024 08:02:00 PM
- Omeros Corporation to Announce Second Quarter Financial Results on August 7, 2024 • Business Wire • 08/05/2024 08:02:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/12/2024 08:48:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:13:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:12:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:10:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:08:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:07:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 09:05:53 PM
- Omeros Announces Webcast Details for Annual Meeting of Shareholders • Business Wire • 06/04/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/03/2024 01:00:24 PM
- Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 • Business Wire • 06/03/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2024 08:09:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:07:40 PM
- Omeros Corporation Reports First Quarter 2024 Financial Results • Business Wire • 05/15/2024 08:02:00 PM
- Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 • Business Wire • 05/10/2024 12:50:00 PM
- Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress • Business Wire • 05/09/2024 12:50:00 PM
- Omeros Corporation Reports Fourth Quarter and Year-End 2023 Financial Results • Business Wire • 04/01/2024 08:02:00 PM
- Omeros Corporation to Announce Fourth Quarter and Year-End Financial Results on April 1, 2024 • Business Wire • 03/27/2024 12:30:00 PM
- Omeros Corporation Announces Upcoming Presentation Detailing Narsoplimab Compassionate Use in Nine Patients with Hematopoietic Stem Cell Transplant-associated Thrombotic Microangiopathy • Business Wire • 02/20/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 11:05:17 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:23 PM
- Omeros Corporation Announces Additional Royalty Monetization with DRI Healthcare Trust • Business Wire • 02/01/2024 02:11:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM